Description:MRTX-849, also known by its chemical name as a selective inhibitor of KRAS G12C, is a small molecule designed for targeted cancer therapy. It specifically binds to the KRAS G12C mutant protein, which is commonly associated with various cancers, including non-small cell lung cancer and colorectal cancer. The compound works by locking the KRAS protein in an inactive state, thereby inhibiting its signaling pathways that promote tumor growth and survival. MRTX-849 has shown promise in preclinical and clinical studies, demonstrating efficacy in reducing tumor size and improving patient outcomes. Its pharmacokinetic properties include oral bioavailability, allowing for convenient administration. Additionally, the compound is characterized by its specificity for the G12C mutation, minimizing effects on wild-type KRAS and potentially reducing side effects. As a part of ongoing research, MRTX-849 is being evaluated in combination with other therapies to enhance its effectiveness and overcome resistance mechanisms in cancer treatment.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
